-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adagrasib in Gynecological Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adagrasib in Gynecological Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adagrasib in Gynecological Cancer Drug Details: Adagrasib (Krazati) belongs to the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD70 CAR-T Cells in Gynecological Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD70 CAR-T Cells in Gynecological Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD70 CAR-T Cells in Gynecological Cancer Drug Details: Gene-modified cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-099280 in Gynecological Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-099280 in Gynecological Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCB-099280 in Gynecological Cancer Drug Details: INCB-099280 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – STX-478 in Gynecological Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - STX-478 in Gynecological Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. STX-478 in Gynecological Cancer Drug Details: STX-478 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab Zovodotin in Gynecological Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanidatamab Zovodotin in Gynecological Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zanidatamab Zovodotin in Gynecological Cancer Drug Details:Zanidatamab Zovodotin is under development for the...
-
Thematic Analysis
NewInflation in Medical Devices – Thematic Intelligence
Inflation in Medical Devices Thematic Report Overview Even though COVID-19 vaccines and testing allowed economies and societies to safely reopen, supply-demand imbalance, inflation, recession prospects, market volatility, and geopolitical tensions and conflicts inject instability into the economic recovery and growth prospects. According to GlobalData’s Inflation Impact on the Healthcare Industry Survey (H2 2023), inflation, geopolitical conflicts, and reimbursement constraints may have the greatest negative impact on the medical device industry in 2024. These will have a reciprocal impact on healthcare...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Colorectal Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Gastric Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Hepatocellular Carcinoma Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Endometrial Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...